HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Anticoagulant protein S in COVID-19: low activity, and associated with outcome.

Abstract
Introduction. COVID-19 disease was associated with both thrombo-embolic events and in-situ thrombi formation in small vessels. Antiphospholipidic antibodies were found in some studies.Aim. Assessment of protein S activity in patients with COVID-19 as a cause of this prothrombotic state, and of the association of protein S activity with worse outcome.Methods. All patients admitted for COVID-19 disease in a university hospital between 15th of May and 15th of July 2020 were prospectively enrolled into this cohort study. Patients treated with antivitamin K anticoagulants and with liver disease were excluded. All patients had protein S activity determined at admission. The main outcome was survival, while secondary outcomes were clinical severity and lung damage.Results. 91 patients were included, of which 21 (23.3%) died. Protein S activity was decreased in 65% of the patients. Death was associated with lower activity of protein S (median 42% vs. 58%, p < 0.001), and the association remained after adjustment for age, inflammation markers and ALAT. There was a dose-response relationship between protein S activity and clinical severity (Kendall_tau coefficient = -0.320, p < 0.001; Jonckheere-Terpstra for trend: p < 0.001) or pulmonary damage on CT scan (Kendall_tau coefficient = -0.290, p < 0.001; Jonckheere-Terpstra for trend: p < 0.001). High neutrophil count was also independently associated with death (p = 0.002).Conclusion. Protein S activity was lower in COVID-19 patients, and its level was associated with survival and disease severity, suggesting that it may have a role in the thrombotic manifestations of the disease.
AuthorsLaura Elena Stoichitoiu, Larisa Pinte, Marius Ioan Balea, Valentin Nedelcu, Camelia Badea, Cristian Baicus
JournalRomanian journal of internal medicine = Revue roumaine de medecine interne (Rom J Intern Med) Vol. 58 Issue 4 Pg. 251-258 (Dec 01 2020) ISSN: 2501-062X [Electronic] Germany
PMID32841167 (Publication Type: Journal Article)
Copyright© 2020 Laura Elena Stoichitoiu et al., published by Sciendo.
Chemical References
  • PROS1 protein, human
  • Protein S
Topics
  • COVID-19 (blood, complications, diagnostic imaging, immunology)
  • Humans
  • Leukocyte Count
  • Lung (diagnostic imaging)
  • Neutrophils
  • Prospective Studies
  • Protein S (metabolism)
  • SARS-CoV-2
  • Severity of Illness Index
  • Survival Analysis
  • Thromboembolism (virology)
  • Tomography, X-Ray Computed

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: